gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
other
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Belrestotug binds TIGIT on target immune cells and its Fc engages CD16a on NK cells to mediate ADCC against TIGIT+ cells (e.g., Tregs). CD16a+ cells serve as effectors and are not killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-enabled IgG1 engagement mediating ADCC of TIGIT+ cells; effector mechanism rather than primary tumor antigen target
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06062420
disease_id_num_tar_ref
818
drug_id_num_tar_ref
2268